कंपनी का अवलोकन
Achieve Life Sciences, Inc. is a late-stage pharmaceutical entity dedicated to the development and commercialization of cytisinicline, a plant-based alkaloid designed to assist individuals with nicotine independence across the markets of Canada, the United States, and the United Kingdom. This organization operates within the Healthcare sector, specifically functioning in the Biotechnology industry, where it focuses on advancing novel therapeutic compounds derived from natural sources to address addiction medicine. The company maintains a market capitalization of $176.76M and employs a workforce of 28 individuals to execute its strategic initiatives. These valuation metrics, combined with the absence of reported annual revenue in the available data, indicate that the firm is currently in a capital-intensive development phase where market value is derived primarily from intellectual property potential rather than established sales streams. The relatively small employee count suggests a lean operational structure typical of biotechnology firms concentrating resources on high-value research and regulatory approvals.
वित्तीय स्वास्थ्य
The financial statements for the trailing twelve months (TTM) report a revenue figure of N/A, alongside a net income of $-54,648,000 and an EBITDA of $-54,652,000. The substantial gap between the negligible revenue and the significant negative net income reveals a cost structure dominated by research, development, and operational expenses rather than sales costs. The free cash flow stands at $-28,461,876, indicating that the company is consuming cash reserves to fund its growth initiatives and R&D activities. While the balance sheet shows a cash position of $36.40M, this liquidity is partially offset by a total debt obligation of $14.96M. The debt-to-equity ratio of 69.50 suggests that the company utilizes a significant amount of leverage relative to its shareholders' equity, which is a common characteristic for pre-revenue biotechnology firms seeking to optimize capital efficiency. The current ratio is reported at 4.39, which indicates a robust short-term liquidity position capable of covering current liabilities multiple times over. However, the return on equity (ROE) is -257.7% and the return on assets (ROA) is -85.3%, metrics that reveal the company is currently destroying shareholder value and asset efficiency due to its heavy investment in future product commercialization.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is N/A, while the forward P/E is listed as -3.20, implying that the market anticipates continued negative earnings in the near term due to ongoing development costs. The price-to-book ratio is 8.22, which indicates that the stock is trading at a significant premium relative to its net asset value, reflecting the high valuation placed on its pipeline assets. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -2.84, suggest that traditional valuation multiples are not applicable due to the lack of profitability and revenue data. The 52-week trading range spans from a low of $1.84 to a high of $6.03, and based on the forward P/E of -3.20 and the available data context, the stock trades within a volatile band driven by biotechnology sector dynamics. The beta value of 1.96 indicates that the stock exhibits high volatility, moving nearly twice as much as the broader market in response to changes in sentiment or sector-specific news.
Growth & Income
The revenue growth year-over-year is N/A, and the earnings growth year-over-year is also N/A, as the company has not yet generated positive sales to calculate comparative growth rates. Consequently, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are technically retained for reinvestment into the business rather than distributed to shareholders. The absence of a dividend payout ratio implies that the firm is in a reinvestment phase where capital is directed toward expanding the cytisinicline program and securing regulatory approvals. The overall growth and income profile is characterized by a lack of current profitability and income generation, relying entirely on the successful future commercialization of its asset in the nicotine independence market to realize value for stakeholders.